Pharmaxis' asthma test Aridol gets approval from Therapeutic Goods Administration

By Elaine Rigoli

Tampa, Fla., March 23 - Pharmaxis Ltd. said the Therapeutic Goods Administration (TGA) has approved its first product, Aridol, for commercial sale in Australia.

Aridol is designed to identify patients with active asthma and provide information on the severity of the disease and the effectiveness of their current treatment, according to a company news release.

More than 2 million people in Australia and 52 million people worldwide live with the disease. Currently, there is no registered, objective test to measure inflammation and hyper-responsiveness in the airways - the symptoms of active asthma. Aridol will fill this gap, the release said.

"The assistance and advice of the TGA has been very helpful as we have moved Aridol through its development and evaluation to final commercialization. We have full commercial rights to Aridol, and we can now set about building a profitable Aridol business," chief executive officer Alan Robertson said in the release.

Initially Aridol will be made available to respiratory specialists and laboratories, officials said.

Pharmaxis will market Aridol directly in Australia and is negotiating European marketing agreements.

Sydney, Australia-based Pharmaxis is a specialist pharmaceutical company involved in the research, development and commercialization of therapeutic products for chronic respiratory and autoimmune diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.